Tomorrow’s cure lies not in a universal pill, but within our own genetic code.
— Jim Carroll
The opportunity
Precisely correct the underlying genetic mutations responsible for inherited disorders, offering the potential for one-time cures and transforming the lives of patients.
From “Megatrends One Year Later – #12: Personalized Medicine – What I Predicted, and What’s Actually Happening” (August 2026)
We are combining next-generation genomic sequencing, AI, and CRISPR gene editing, to come up with a new health paradigm that involves fixing people before they are sick rather than after.
In February 2026 the FDA introduced a novel regulatory framework specifically for individualized gene-editing therapies. Around the same time, a Philadelphia team developed, got approved, and delivered a personalized CRISPR therapy to a nine-month-old infant with a rare genetic disorder — in six months, start to finish. There are now 4,469 gene and cell therapies in active development — 49% gene therapies, 29% RNA therapies. That’s the “writing the code” pillar, and it’s real.
Verdict: Nailed it — and it’s bigger than gene editing alone. CRISPR is the headline, but the P4 framework — predictive, personalized, preventive, participatory — is now running quietly in the background of a normal doctor’s visit.
From “Decoding Tomorrow: 30 Megatrends - #12 Personalized Medicine: “Tomorrow’s cure lies not in a universal pill, but within our own genetic code.”” (July 2025)
What’s it all about? We are combining what we might call ’ next-generation genomic sequencing ’, AI, and CRISPR gene editing, to come up with a new health paradigm that involves ’ fixing people before they are sick rather than after .’ Why these 3 trends? The cost for genomic sequencing is collapsing, AI is accelerating the ability to do so, and gene editing allows us to correct the genetic causes of disease at the source.
That came about as we saw the emergence of several transformative technologies - wearables, AI, and gene editing. These are the engines of the personalized era. A convergence of capabilities—allowing us to read, write, and interpret the code of life with unprecedented efficiency—has created a powerful engine driving the entire field forward.
One of these key capabilities is ” writing” the code. If Next-Generation Sequencing (NGS) gave us the ability to read the code of life, CRISPR-Cas9 gives us the ability to write it, or ‘edit’ it. This allows scientists can introduce specific changes, opening up revolutionary possibilities for directly correcting underlying genetic mutations that cause many diseases and conditions. This is a pretty profound opportunity.
From “Decoding Tomorrow: The Way Forward: #4 Healthcare: “Yesterday’s medical breakthrough was a new drug. Tomorrow’s breakthrough is the intelligent algorithm that designs the drug, the connected device that delivers it, and the data stream that confirms it worked.”” (September 2025)
What does it lead to? Consider the global regenerative medicine market, which is projected to surge from $35.47 billion in 2024 to $90.01 billion by 2030 - we’ll soon be growing human body parts. That might be a bit of a stretch, but maybe not. Then there is the promise that gene therapy is finally being realized. In 2023, the FDA granted special designation to EDIT-301, a groundbreaking CRISPR gene-editing drug for severe sickle cell disease. In one remarkable case, a bespoke CRISPR treatment for a rare genetic disorder was developed for an infant in under six months, a feat made possible only through rapid collaboration across academia, industry, and regulators.
A 2024 PwC survey starkly illustrates the economic necessity driving this trend: seven out of ten consumers report that they either cannot afford their current healthcare costs or cannot afford to pay more . This financial pressure is the primary driver behind the demand for tools that allow patients to compare prices and make informed decisions. Modern platforms like Relatient are creating a comprehensive ” digital front door, ” offering Amazon-like healthcare experiences, with digital intake, secure two-way communication, and automated satisfaction surveys to create a seamless digital experience.
Erection of Regulatory Barriers : A more skeptical or politicized regulatory environment could slow the approval of novel technologies like gene therapies and AI-driven diagnostic tools.
Read the full pieces on jimcarroll.com:
Megatrends One Year Later – #12: Personalized Medicine – What I Predicted, and What’s Actually Happening
Decoding Tomorrow: 30 Megatrends - #12 Personalized Medicine: “Tomorrow’s cure lies not in a universal pill, but within our own genetic code.”
Decoding Tomorrow: The Way Forward: #4 Healthcare: “Yesterday’s medical breakthrough was a new drug. Tomorrow’s breakthrough is the intelligent algorithm that designs the drug, the connected device that delivers it, and the data stream that confirms it worked.”